Cipla Receives USFDA Approval to Market Lanreotide Injection
Cipla Receives USFDA Approval to Market Lanreotide Injection

Cipla, a major pharmaceutical company, has obtained approval from the US Food and Drug Administration (FDA) to market its Lanreotide injection, a generic medication used to treat acromegaly and other conditions. The Mumbai-based drug maker announced the final approval on Wednesday, highlighting that its product is a therapeutic equivalent of Somatuline Depot Injection.

Lanreotide Injection is primarily indicated for the treatment of acromegaly and gastroenteropancreatic neuroendocrine tumors. According to IQVIA (IMS Health), Somatuline Depot, the branded drug, achieved sales of approximately USD 898 million in the US during the 12-month period ending March 2024.

LANREOTIDE (lan REE oh tide) is a medication prescribed to lower blood levels of growth hormone in patients diagnosed with acromegaly. Additionally, it is effective in slowing or halting tumor growth in individuals suffering from neuroendocrine tumors and in managing symptoms of carcinoid syndrome. This therapy helps to alleviate the symptoms associated with these conditions and improves the overall quality of life for patients undergoing treatment.

This approval allows Cipla to introduce its generic version of Lanreotide injection in multiple strengths to the US market, contributing to its portfolio of affordable and effective treatments.


Cipla's approval to market Lanreotide injection marks a significant milestone for the company, expanding its presence in the US pharmaceutical market. Acromegaly, a rare hormonal disorder, and gastroenteropancreatic neuroendocrine tumors are serious conditions that affect patients' quality of life, and the availability of a generic alternative like Lanreotide injection provides a more accessible treatment option. With this approval, Cipla aims to make a meaningful impact by offering a cost-effective solution that meets the therapeutic needs of patients, further reinforcing its commitment to healthcare accessibility and affordability.

Mahindra Launches XUV700 AX5 S Variant with Sunroof and Dual Screens, Check Revised Price Here

How Eating Right Can Ward Off Disease and Slow Aging

Be Positive: How a Positive Mindset Can Transform Your Health

Join NewsTrack Whatsapp group
Related News